OpenFilings

REGENERON PHARMACEUTICALS, INC.

Form10-Q

Report Period2024-03-31

Date Filed2024-05-02

Time Filed07:13:11

Document Analysis

Natural Language Processing

Recognized Type Unidentified

Defined Term Format

Exhibits

10-Q
AMENDMENT NO.2 TO MASTER AGREEMENT BETWEEN REGN AND ALNYLAM
CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)
CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)
CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350
Filing on SEC Edgar